| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 10 | -349K | 100% | $31.91 | -$11.1M |
| Net | -10 | -349K | -100% | -$11.1M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10%+ Owner | $3.03B | Oct 2, 2023 | ||
| Peter Salzmann | Chief Executive Officer, Director | $28.6M | -$4.05M | -12.4% | Oct 16, 2024 |
| Frank Torti | Director | $23M | Apr 2, 2024 | ||
| Julia G. Butchko | Chief Development Officer | $14.3M | -$882K | -5.83% | Aug 21, 2024 |
| William L. Macias | Chief Medical Officer | $10.5M | -$820K | -7.24% | Oct 16, 2024 |
| Eva Renee Barnett | Chief Financial Officer | $9.65M | -$1.57M | -14% | Oct 16, 2024 |
| Mark S. Levine | Chief Legal Officer | $9.53M | -$1.3M | -12% | Oct 23, 2024 |
| Douglas J. Hughes | Director | $4.52M | Apr 2, 2024 | ||
| George V. Migausky | Director | $4.38M | -$505K | -10.3% | Apr 2, 2024 |
| Jay S. Stout | Chief Technology Officer | $4.2M | -$368K | -8.06% | Oct 23, 2024 |
| Atul Pande | Director | $4.14M | -$491K | -10.6% | Apr 2, 2024 |
| Michael Geffner | Chief Medical Officer | $3.99M | -$667K | -14.3% | Oct 23, 2024 |
| Andrew J. Fromkin | Director | $3.61M | -$491K | -12% | Apr 2, 2024 |
| Melanie Gloria | Chief Operating Officer | $3.25M | Nov 18, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|